01652.HK
Fusen Pharmaceutical Company Limited
HKSE · Healthcare · Drug Manufacturers - Specialty & Generic · CN
HKD 0.74
−5.73%Aug 3, 2026, 09:48 UTC
Fusen Pharmaceutical announced that four of its products were provisionally selected in China's 12th national centralized drug procurement tender on July 31, 2026.
Source:Jul 13, 2026, 02:18 UTC
Fusen Pharmaceutical's subsidiary Henan Fusen Pharmaceutical received approval from the National Medical Products Administration to market its drug Doxazosin Mesylate Extended-Release Tablets (trademark: Yijianping) for the treatment of mild-to-moderate hypertension and benign prostatic hyperplasia.
Source: